Revenue (Annual)

Revenue: The sum of all revenue fields included for a company's operating activities.

Ocular Therapeutix, Inc. (OCUL) had Revenue of $63.72M for the most recently reported fiscal year, ending 2024-12-31.

Quarterly Annual

Figures for fiscal year ending 2024-12-31

Income Statement Financials
Revenue	$63.72M
Net Income	$-193.51M
Cost of Goods Sold	$5.63M
Gross Profit	$58.10M
Operating Expenses	$235.50M
Operating Income	$-171.78M
Non-Operating Income/Expense	$-21.73M
Pre-Tax Income	$-193.51M
Normalized Pre-Tax Income	$-193.51M
Income after Taxes	$-193.51M
Income from Continuous Operations	$-193.51M
Consolidated Net Income/Loss	$-193.51M
Normalized Income after Taxes	$-193.51M
EBIT	$-171.78M
EBITDA	$-168.00M
Weighted-Average Shares Outstanding (Basic)	158.26M
Weighted-Average Shares Outstanding (Diluted)	158.26M
Earnings per Share (EPS) (Basic)	$-1.22
Earnings per Share (EPS) (Diluted)	$-1.22
Balance Sheet Financials
Current Assets	$440.99M
Property, Plant, and Equipment	$9.39M
Long-Term Assets	$16.95M
Total Assets	$457.94M
Current Liabilities	$41.35M
Long-Term Debt	$68.50M
Long-Term Liabilities	$101.24M
Total Liabilities	$142.59M
Common Equity	$315.34M
Tangible Shareholders Equity	$315.34M
Shareholders Equity	$315.34M
Common Shares Outstanding	157.75M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$-134.68M
Cash Flow from Investing Activities	$-1.29M
Cash Flow from Financial Activities	$332.11M
Beginning Cash	$197.57M
End Cash	$393.72M
Increase/Decrease in Cash	$196.15M
Stock-Based Compensation	$33.11M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	10.66
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.18
Debt to Equity Ratio	0.22
Gross Margin	91.17%
Operating Margin	-269.57%
EBIT Margin	-269.57%
EBITDA Margin	-263.63%
Pre-Tax Profit Margin	-303.67%
Profit Margin	-303.67%
Free Cash Flow	$-135.97M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.14
Inventory Turnover	1.85
Receiveable Turnover	1.97
Days Sales in Receivables	185.52
Return on Equity	-61.36%
Return on Tangible Equity	-61.36%
Return on Assets	-42.26%
Return on Investments	-50.41%
Book Value Per Share	$2.00
Free Cash Flow per Share	$-0.86
Operating Cash Flow per Share	$-0.85

Data from Zacks Investment Research, Inc.